{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:07:16Z","timestamp":1792192036183,"version":"4.4.0"},"reference-count":16,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL076136"],"award-info":[{"award-number":["T32HL076136"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL137562, R01HL130539, K24HL150238"],"award-info":[{"award-number":["R01HL137562, R01HL130539, K24HL150238"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Curtis Greer and Pamela Kohlberg"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy. Beyond switching to non-5FU-based chemotherapy, there are no established treatments for 5-FU associated coronary vasospam. Our objective was to assess the safety and efficacy of re-challenge with 5-FU after pre-treatment with calcium channel blockers (CCBs) and long-acting nitrates among patients 5-FU associated coronary vasospasm.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a retrospective study of patients with 5-FU coronary vasospasm at a single academic center. By protocol, those referred to cardio-oncology received pre-treatment with either combination [nitrates and CCBs] or single-agent therapy [nitrates or CCBs]) prior to re-challenge with 5-FU. Our primary outcome was overall survival. Other important outcomes included progression-free survival and safety.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among 6,606 patients who received 5-FU from January 2001 to Dec 2020, 115 (1.74%) developed coronary vasospasm. Of these 115 patients, 81 patients continued 5-FU therapy, while 34 stopped. Of the 81 who continued, 78 were referred to cardio-oncology and prescribed CCBs and\/or nitrates prior to subsequent 5-FU, while the remaining 3 continued 5-FU without cardiac pre-treatment. Of the 78, 56.4% (44\/78) received both nitrates and CCBs, 19.2% (15\/78) received CCBs alone, and 24.4% (19\/78) received nitrates alone. When compared to patients who stopped 5-FU, those who continued 5-FU after pre-treatment (single or combination therapy) had a decreased risk of death (HR 0.42, P = 0.005 [95% CI 0.23\u20130.77]) and a trend towards decreased cancer progression (HR 0.60, P = 0.08 [95% CI 0.34\u20131.06]). No patient in the pre-treatment group had a myocardial infarct after re-challenge; however, chest pain (without myocardial infarction) recurred in 19.2% (15\/78) among those who received cardiac pre-treatment vs. 66.7% (2\/3) among those who did not (P = 0.048). There was no difference in efficacy or the recurrence of vasospasm among patients who received pre-treatment with a single agent (nitrates or CCBs) or combination therapy (14.7% (5\/34) vs. 25.0% (11\/44), P = 0.26).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Re-challenge after pre-treatment with CCBs and nitrates guided by a cardio-oncology service was safe and allowed continued 5-FU therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0265767","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T18:02:45Z","timestamp":1649354565000},"page":"e0265767","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2010-3018","authenticated-orcid":true,"given":"Amna","family":"Zafar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia D.","family":"Drobni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-2086","authenticated-orcid":true,"given":"Carlos A.","family":"Gongora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9099-3007","authenticated-orcid":true,"given":"Thiago","family":"Quinaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9220-3646","authenticated-orcid":true,"given":"Uvette Y.","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Mosarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Jones-O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Gilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin D.","family":"Weekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Nipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Blaszkowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G.","family":"Neilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"issue":"6","key":"pone.0265767.ref001","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management","volume":"18","author":"ME Layoun","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"pone.0265767.ref002","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"JD Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"pone.0265767.ref003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","article-title":"Fluoropyrimidine-induced cardiotoxicity","volume":"124","author":"I Depetris","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"pone.0265767.ref004","first-page":"430","article-title":"A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center","volume":"62","author":"MA Khan","year":"2012","journal-title":"J Pak Med Assoc"},{"issue":"4","key":"pone.0265767.ref005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003495-199957040-00003","article-title":"Cardiotoxicity of the antiproliferative compound fluorouracil","volume":"57","author":"K Becker","year":"1999","journal-title":"Drugs"},{"issue":"4","key":"pone.0265767.ref006","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-020-0719-1","article-title":"Cardiotoxicities of 5-Fluorouracil and Other Fluoropyrimidines","volume":"21","author":"T Shiga","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"pone.0265767.ref007","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15420\/icr.2019.12","article-title":"Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions","volume":"14","author":"JH Chong","year":"2019","journal-title":"Interv Cardiol"},{"issue":"24","key":"pone.0265767.ref008","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"EA Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"pone.0265767.ref009","first-page":"650","article-title":"How to Diagnose and Manage Patients With Fluoropyrimidine-Induced Chest Pain","volume":"2","author":"A Padegimas","year":"2020","journal-title":"JACC: CardioOncology"},{"issue":"4","key":"pone.0265767.ref010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00000441-198710000-00004","article-title":"5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators","volume":"294","author":"B Patel","year":"1987","journal-title":"Am J Med Sci"},{"key":"pone.0265767.ref011","first-page":"205","article-title":"5-fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study","volume":"10","author":"N. Tsavaris CK","year":"2005","journal-title":"Journal of BUON"},{"issue":"11","key":"pone.0265767.ref012","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.amjcard.2012.07.026","article-title":"Capecitabine-induced chest pain relieved by diltiazem","volume":"110","author":"AP Ambrosy","year":"2012","journal-title":"Am J Cardiol"},{"issue":"6","key":"pone.0265767.ref013","doi-asserted-by":"crossref","first-page":"970","DOI":"10.21037\/jgo.2017.09.07","article-title":"Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm","volume":"8","author":"SC Clasen","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"pone.0265767.ref014","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3109\/02841869009091790","article-title":"Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil","volume":"29","author":"J Eskilsson","year":"1990","journal-title":"Acta Oncol"},{"key":"pone.0265767.ref015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2017.05.022","article-title":"Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm","volume":"81","author":"JJM Kwakman","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"pone.0265767.ref016","first-page":"101","article-title":"The Incidence, Risk Factors, and Outcomes With 5-Fluorouracil\u2013Associated Coronary Vasospasm","volume":"3","author":"A Zafar","year":"2021","journal-title":"JACC: CardioOncology."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0265767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T18:03:03Z","timestamp":1649354583000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0265767"}},"subtitle":[],"editor":[{"given":"Yoshiaki","family":"Taniyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0265767","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}